No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19

Figure 1 Flow chart of study inclusion. T2D: Type 2 diabetes; DPP4i: Dipeptidyl peptidase-4 inhibitors.

Figure 2 Box plots showing the median levels of inflammatory response indicators in dipeptidyl peptidase-4 inhibitor and non-dipeptidyl peptidase-4 inhibitor groups (n = 444). A-F: Box chart analysis of median levels of neutrophil count, neutrophil percentage, leukocyte count, tumor necrosis factor-α, interleukin (IL)-6, and IL-10 between the dipeptidyl peptidase-4 inhibitor (DPP4i) and non-DPP4i groups. The median levels of those parameters of each participant during the follow-up duration were applied and were normalized according to their upper limits of normal range of each hospital. DPP4i: Dipeptidyl peptidase-4 inhibitors; TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; IL-10: Interleukin-10.